Characterization and prevention of chemotherapy induced cardiac dysfunction
Background: Anthracyclines, in particular Doxorubicin (DOX), are highly effective chemotherapeutic agents in the breast cancer setting, which are limited by their cardiotoxic side effects. Recently, the introduction of Trastuzumab (TRZ), a novel monoclonal antibody against the HER2 receptor, in the...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
2012
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1993/8119 |